Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 2, 2012, Pages 299-307

  Saeed, Omar ^a   Otsuka, Fumiyuki ^c   Polavarapu, Rohini ^a   Karmali, Vinit ^a   Weiss, Daiana ^a   Davis, Talina ^a   Rostad, Brad ^a   Pachura, Kimberly ^a   Adams, Lila ^c   Elliott, John ^a   Taylor, W Robert ^a,b   Narula, Jagat ^f   Kolodgie, Frank ^c   Virmani, Renu ^c   Hong, Charles C ^d,e,g   Finn, Aloke V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emory University   (United States)

^c CVPATH INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporter; hemoglobin; macrophages; pharmacology; reactive oxygen species

Indexed keywords

4 [6 (4 PIPERAZIN 1 YLPHENYL)PYRAZOLO[1,5 A]PYRIMIDIN 3 YL]QUINOLINE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN; CHOLESTEROL; FERROPORTIN; HEPCIDIN; HYDROGEN PEROXIDE; IRON; LDN 193189; PROTEIN INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FOAM CELL; HEART EJECTION FRACTION; HEART FUNCTION; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; IRON BLOOD LEVEL; LIPID TRANSPORT; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CHOLESTEROL; DISEASE MODELS, ANIMAL; FOAM CELLS; IRON; LIPOPROTEINS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84856225143     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.240101     Document Type: Article

References (28)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51: 2199-2211.
4. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117:3900-3908.
5. Out R, Hoekstra M, Habets K, Meurs I, de Waard V, Hildebrand RB, Wang Y, Chimini G, Kuiper J, Van Berkel TJ, Van Eck M. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2008;28:258-264.
6. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216-2224.
7. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, Van Berkel TJ. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:929-934.
8. Finn AV, Nakano M, Polavarapu R, Karmali V, Saeed O, Zhao X, Yazdani S, Otsuka F, Davis T, Habib A, Narula J, Kolodgie FD, Virmani R. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012, in press.
9. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306: 2090-2093.
10. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008; 4:33-41.
11. Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol. 2010;42:1802-1807.
12. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14: 1363-1369.
13. Kong WN, Zhao SE, Duan XL, Yang Z, Qian ZM, Chang YZ. Decreased DMT1 and increased ferroportin 1 expression is the mechanisms of reduced iron retention in macrophages by erythropoietin in rats. J Cell Biochem. 2008;104:629-641.
14. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106: 2196-2199.
15. Finn AV, John M, Nakazawa G, Polavarapu R, Karmali V, Xu X, Cheng Q, Davis T, Raghunathan C, Acampado E, Ezell T, Lajoie S, Eppihimer M, Kolodgie FD, Virmani R, Gold HK. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor γ agonists: requirement for mTOR/Akt2 in PPAR γ activation. Circ Res. 2009; 105:1003-1012.
16. Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. 2008;181:2723-2731.
17. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
18. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001;103:448-454.
19. Finn AV, Kramer MC, Vorpahl M, Kolodgie FD, Virmani R. Pharmacotherapy of coronary atherosclerosis. Expert Opin Pharmacother. 2009; 10:1587-1603.
20. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008;18:4388-4392.
21. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, Hopkins CR, Lindsley CW, Hong CC. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol. 2010;5:245-253.
22. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357: 1301-1310.
23. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29:1930-1936.
24. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921-2931.
25. Rigamonti E, Helin L, Lestavel S, Mutka AL, Lepore M, Fontaine C, Bouhlel MA, Bultel S, Fruchart JC, Ikonen E, Clavey V, Staels B, Chinetti-Gbaguidi G. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res. 2005;97:682-689.
26. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, Bostrom KI. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010;107: 485-494.
27. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006;38:1424-1429.
28. Corriere MA, Rogers CM, Eliason JL, Faulk J, Kume T, Hogan BL, Guzman RJ. Endothelial Bmp4 is induced during arterial remodeling: effects on smooth muscle cell migration and proliferation. J Surg Res. 2008;145:142-149.